Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.

1. MPC: 7066 – chemistry
Name : Omer Shaikh
caring for life
Cipla

2. Content
 About Cipla
 History
 Ceo of Cipla
 Products and services
 Operations
 Shareholding
 Awards and recognition
 Generic drugs
 Mission statement
 Industry analysis
.
.

3. About Cipla
Cipla Limited is an Indian multinational
pharmaceutical company, headquartered in Mumbai,
India. Cipla primarily develops medicines to treat
respiratory, cardiovascular disease, arthritis, diabetes,
weight control and depression other medical conditions.
Established in 1935, Cipla is a global pharmaceutical
company focused on responsible and sustainable growth
through deep & wide portfolio and strong customer
relationships across our home markets of India, South
Africa, US and other key regulated and emerging
markets.
the strengths in the respiratory, anti-retroviral, urology,
cardiology and CNS segments are well-known.
Our 46 manufacturing facilities around the world
produce 50+ dosage forms and 1,500+ products using
cutting-edge technology platforms to cater to our 80+
markets. Cipla is ranked 3rd largest in pharma
in India and 3rd largest in the pharma private market
in South Africa

4. Yusuf Ahmed
Khwaja Abdul Hamied
History
It was founded by Khwaja Abdul
Hamied as 'The Chemical, Industrial &
Pharmaceutical Laboratories' in 1935
in Mumbai. The name of the Company
was changed to 'Cipla Limited' on 20
July 1984. In the year 1985, US FDA
approved the company's bulk drug
manufacturing facilities. Led by the
founder's son Yusuf Hamied, a
Cambridge-educated chemist, the
company provided generic AIDS and
other drugs to treat poor people in the
developing world. In 1995, Cipla
launched Deferiprone, the world's first
oral iron chelator. In 2001, Cipla
offered medicines (antiretroviral) for
HIV treatment at a fractional cost (less
than $350 per year per patient).

5. Products and services
 Cipla sells active pharmaceutical ingredients to other
manufacturers as well as pharmaceutical and personal care
products, including Escitalopram (anti-depressant),
Lamivudine and Fluticasone propionate. They are the
world's largest manufacturer of antiretroviral drugs.
 In July 2020, the company announced the introduction of
Gilead Sciences' Remdesivir under the brand name
CIPREMI in India after reaching an voluntary licensing
agreement with parent company and DCGI approval for
"restricted emergency use" in COVID-19 treatment of
critical confirmed patients

6. Ceo of Cipla
Mr. Umang Vohra
Managing Director & Global Chief
Executive Officer
Mr. Umang Vohra joined Cipla
Limited in 2015 and has been the
MD & GCEO of the Company since
September 2016. After gaining
degrees in engineering, marketing
and finance, Mr. Vohra worked with
Eicher Motors, PepsiCo and Dr
Reddy’s Laboratories. Through his
previous roles in India and the US,
he has built a distinguished career
spanning almost two decades with
deep understanding and experience
of various aspects of the global
pharmaceutical business.

7. Operation
.
.
.
Cipla has 34 manufacturing units in 8 locations across
India and a presence in over 80 countries. Exports
accounted for 48% ₹4,948 crore (equivalent to ₹68
billion or US$950 million in 2019) of its revenue for FY
2013–14. Cipla spent INR 517 cr. (5.4% of revenue) in
FY 2013–14 on R&D activities. The primary focus areas
for R&D were development of new formulations, drug-
delivery systems and APIs (active pharmaceutical
ingredients). Cipla also cooperates with other
enterprises in areas such as consulting, commissioning,
engineering, project appraisal, quality control, know-
how transfer, support, and plant supply.

8. Shareholding
.
.
8%
18%
18%
9%
19%
0%0%
28%
Revenue Net income Diluted EPS
Net profit margin Operating income Net change in cash
Cash on hand Cost of revenue
0.00% 200.00% 400.00% 600.00% 800.00% 1000.00%1200.00%1400.00%
Chart Title
Promoter Group Foreign Institutional Investors (FII)
Individual shareholders Insurance companies
Private Corporate Bodies Mutual Funds and UTI
NRI/FCB/Others GDRs
Total

9. Awards and recognition
. . .
 In 2012, Cipla
received the
Thomson Reuters
India Innovation
Award.
 Cipla won Dun &
Bradstreet American
Express Corporate
Awards in 2006.
 In 2007, Forbes included
Cipla in the 200 'Best
under a billion' list of
best small Asian
companies.
 In 1980, Cipla won
Chemexcil Award
for Excellence for
exports

10. Generic drugs
 The CEO of Cipla reached the government
of Indira Gandhi to change India's patent
laws to eliminate patents that directly
covered drugs, and instead to allow only
patents that covered methods to make
drugs.[43] so that Cipla could go ahead and
produce as many low-priced generic drugs
for the poor as possible.
 In the late 1960s, Cipla began
manufacturing a new, patented
drug, propranolol, without the
permission of the drug's patent
holder, Imperial Chemical
Industries (ICI), which protested
to the Indian government.
 Since then Cipla has also produced a
low-cost drug to treat HIV and
expanded operations into several
developing countries, including African
nations, where most HIV and poor
patients existed at one time. But the
changes made led to criticism of both
India's patent laws and Cipla.

11. Mission statement
Cipla mission is to be a
leading global health care
company which uses
technology and
innovation to meet
everyday needs of all
patients.

12. Industry analysis
04
.
05
06
.
01
.
02 03
In the domestic market, Cipla
continued to maintain its leadership
position in various therapeutic
segments including respiratory,
anti-virals, gynecology and urology
for the period 2012-13.
The Company’s domestic
business constitutes ~45 % of
its total revenues. Currently, it
commands 5.7 % market share
(as per AIOCD AWACS) in
domestic pharmaceutical space.
Its domestic business has grown
at a CAGR of 10 % over the last
five years.
The growth in domestic revenues was
largely on account of growth in anti-
asthma, anti-biotics and cardiovascular
therapy segments

13. 0 20000 40000 60000 80000 100000 120000 140000 160000 180000
Sun Pharma
Divis Labs
Dr Reddys Labs
Cipla
Aurobindo Pharm
Torrent Pharma
Lupin
Cadila Health
Abbott India
Alkem Lab
GlaxoSmithKline
Last Price Market Cap. (Rs. cr.) Sales Turnover Net Profit Total Assets

14. Industry analysis
PowerPoint
Presentation
PowerPoint
Presentation
PowerPoint
Presentation
.
.

15. Thank you
.
,